[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neumora Therapeutics Inc (NMRA)

Neumora Therapeutics Inc (NMRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 303,866
  • Shares Outstanding, K 185,284
  • Annual Sales, $ 0 K
  • Annual Income, $ -236,930 K
  • EBIT $ -223 M
  • EBITDA $ -225 M
  • 60-Month Beta 2.74
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.90

Options Overview Details

View History
  • Implied Volatility 141.71% (-113.46%)
  • Historical Volatility 258.50%
  • IV Percentile 18%
  • IV Rank 19.21%
  • IV High 536.33% on 02/05/26
  • IV Low 47.87% on 09/03/25
  • Expected Move (DTE 18) 0.1700 (10.37%)
  • Put/Call Vol Ratio 0.19
  • Today's Volume 147
  • Volume Avg (30-Day) 1,739
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 74,233
  • Open Int (30-Day) 70,905
  • Expected Range 1.4700 to 1.8100

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.23
  • Number of Estimates 4
  • High Estimate $-0.20
  • Low Estimate $-0.30
  • Prior Year $-0.33
  • Growth Rate Est. (year over year) +30.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8302 +97.54%
on 06/15/26
1.9600 -16.33%
on 05/29/26
-0.2000 (-10.87%)
since 05/26/26
3-Month
0.8302 +97.54%
on 06/15/26
2.5500 -35.69%
on 05/01/26
-0.8500 (-34.14%)
since 03/26/26
52-Week
0.7158 +129.11%
on 06/30/25
3.6500 -55.07%
on 02/18/26
+0.8406 (+105.15%)
since 06/26/25

Most Recent Stories

More News
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud

Neumora Therapeutics projected cash runway "into 2027" tied to clinical milestones that never materialized -- then cut 35% of its workforce the same day both pivotal trials failed.

NMRA : 1.6400 (+8.61%)
NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations

Neumora Therapeutics characterized its first failed Phase 3 trial as an "anomaly" and projected 90% statistical power across its navacaprant program -- then both remaining pivotal trials failed, triggering...

NMRA : 1.6400 (+8.61%)
Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)

Neumora Therapeutics reported data from its Phase 3 KOASTAL Program; the stock fell nearly 50%.

NMRA : 1.6400 (+8.61%)
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update

Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant Advancing potential best-in-class programs with NMRA-511 in Alzheimer’s disease...

NMRA : 1.6400 (+8.61%)
SoftBank Just Dumped Circle Stock. Don’t Panic and Keep Adding CRCL Here.

SoftBank fully exited Circle Internet Group in Q1 2026. Here is what investors need to know about the stablecoin giant's fundamentals.

TMUS : 182.68 (+0.61%)
BLK : 964.71 (-0.74%)
META : 550.25 (+1.36%)
LMND : 58.86 (+5.13%)
CRCL : 73.57 (+6.92%)
SFTBY : 19.7100 (-5.60%)
NMRA : 1.6400 (+8.61%)
ICE : 123.86 (-0.51%)
^USDCUSD : 1.000010 (-0.01%)
UBER : 76.20 (+5.47%)
DASH : 183.09 (+3.49%)
LIFE : 19.58 (+5.16%)
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target...

NMRA : 1.6400 (+8.61%)
Neumora's Pipeline Credibility Rests on Two Readouts Due Within Weeks

Barchart Research What to Expect from NMRA Earnings NMRA Generated May 8, 2026 Current Price $1.8300 EPS Estimate $$-0.25 Consensus Rating Moderate Buy Average Move 7.45% Neumora's Pipeline Credibility...

NMRA : 1.6400 (+8.61%)
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 Progressing NMRA-511 in Alzheimer’s disease agitation...

NMRA : 1.6400 (+8.61%)
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference

WATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc.  (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that...

NMRA : 1.6400 (+8.61%)
Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies  KOASTAL-2 and -3 fully enrolled in the first quarter of...

NMRA : 1.6400 (+8.61%)

Business Summary

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. Its therapeutic pipeline currently consists of clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Neumora...

See More

Key Turning Points

3rd Resistance Point 1.8867
2nd Resistance Point 1.7733
1st Resistance Point 1.7067
Last Price 1.6400
1st Support Level 1.5267
2nd Support Level 1.4133
3rd Support Level 1.3467

See More

52-Week High 3.6500
Fibonacci 61.8% 2.5291
Fibonacci 50% 2.1829
Fibonacci 38.2% 1.8367
Last Price 1.6400
52-Week Low 0.7158

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.